TIL
Instil Bio, Inc.
$7.70
+0.04 (+0.52%)
At close · Jul 10
Market Cap
$52.22M
Shares
6,781,976
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2021
Net Income
-$71.37M
+3.7%
FY2025
Diluted EPS
-$10.70
+6.1%
FY2025
Operating Cash Flow
-$36.62M
+34.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | — | — | — | $0 | |
| $8.97M | $8.97M | $4.27M | — | — | — | |
| $20.04M | $24.74M | $11.84M | $39.6M | $141.06M | $107.25M | |
| $23.46M | $27.22M | $44.21M | $47.55M | $62.24M | $48.31M | |
| — | $534K | $3.61M | $4.76M | $5.99M | $2.75M | |
| $55.03M | $78.58M | $73.54M | $159.17M | $226.46M | $155.56M | |
| -$55.03M | -$78.58M | -$73.54M | -$159.17M | -$226.46M | -$155.56M | |
| — | -$78.05M | -$69.93M | -$154.41M | -$220.47M | -$152.81M | |
| $6.28M | $5.83M | $8.99M | $5.21M | $1.88M | — | |
| -$13K | $212K | -$2.86M | -$575K | -$564K | -$1.2M | |
| — | -$71.37M | -$74.14M | -$156.09M | -$225.25M | -$156.76M | |
| — | $0 | — | $0 | -$2.07M | $39K | |
| -$47.38M | -$71.37M | -$74.14M | -$156.09M | -$223.18M | -$156.79M | |
| -$47.46M | -$71.73M | -$74.02M | -$155.94M | -$223.58M | -$156.6M | |
| USD/shares | — | -$10.70 | -$11.39 | -$24.00 | -$34.40 | -$29.60 |
| USD/shares | — | -$10.70 | -$11.39 | -$24.00 | -$34.40 | -$29.60 |
| shares | — | 6.67M | 6.51M | 6.5M | 6.48M | 5.3M |
| shares | — | 6.67M | 6.51M | 6.5M | 6.48M | 5.3M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×